New research suggests that individuals who discontinue popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who halt conventional lifestyle programs.
Research printed in a major medical journal demonstrates that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing such treatments need to be informed of the risk of quick weight regain when the medication concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to original mass within about 18 months.
Analyzing Therapies
The study, which looked at dozens of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with older methods.
The team emphasize that people who lose weight through lifestyle changes alone usually have a more gradual weight regain—around 100 grams monthly—once they finish.
Understanding the Fast Regain
Experts believe the mode of action of the injections accounts for the heightened weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the body to produce less of its own natural hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Condition?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals say that, due to the high risk of relapse, the therapy might need to be life-long.
This perspective is supported by pharmaceutical companies, who state that the results "highlight the chronic character of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
Users who have stopped the medication explain a sudden resurgence of cravings.
"It felt as if something that goes on and I was suddenly starving," recalled a patient.
The struggle is worsened if patients have not established permanent lifestyle or habit changes during therapy.
Growing Interest
Recent estimates indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and lasting health benefits hinges on integrated lifestyle management.
